Basis: Latest reported fiscal year. Source: stored company filings and market data; unavailable inputs remain N/A.
The EBITDA margin is N/A as of Tuesday, October 6, 2026.
EBITDA MARGIN
N/A
Market Cap
$65.87M
EBITDA Margin
-334.74%
TTM Avg
-191.68%
3Y Avg
-191.68%
5Y Avg
-191.68%
Market Cap
$65.85M
EBITDA Margin
-794.91%
TTM Avg
-458.44%
3Y Avg
-317.77%
5Y Avg
-317.77%
Market Cap
$67.52M
EBITDA Margin
-34495.00%
TTM Avg
-19432.00%
3Y Avg
-15233.78%
5Y Avg
-9657.34%
Market Cap
$64.18M
EBITDA Margin
-46.36%
TTM Avg
-44.45%
3Y Avg
-49.00%
5Y Avg
-37.18%
Market Cap
$63.78M
EBITDA Margin
-11538.23%
TTM Avg
-6406.80%
3Y Avg
-3544.47%
5Y Avg
-2835.62%
Market Cap
$68.10M
EBITDA Margin
-103.63%
TTM Avg
-143.63%
3Y Avg
-176.25%
5Y Avg
-194.05%
Market Cap
$68.90M
EBITDA Margin
-0.04%
TTM Avg
-76.47%
3Y Avg
-54.24%
5Y Avg
-650.20%
| NAME | MARKET CAP | EBITDA MARGIN | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| Cingulate Inc. (CING) | $65.86M | N/A | N/A | N/A | N/A |
| Gossamer Bio, Inc. (GOSS)vs › | $65.87M | -334.74% | -191.68% | -191.68% | -191.68% |
| XBiotech Inc. (XBIT)vs › | $65.85M | -794.91% | -458.44% | -317.77% | -317.77% |
| iBio, Inc. (IBIO)vs › | $67.52M | -34495.00% | -19432.00% | -15233.78% | -9657.34% |
| Alps Group Inc (ALPS)vs › | $64.18M | -46.36% | -44.45% | -49.00% | -37.18% |
| Pliant Therapeutics, Inc. (PLRX)vs › | $63.78M | -11538.23% | -6406.80% | -3544.47% | -2835.62% |
| Fortress Biotech, Inc. (FBIO)vs › | $68.10M | -103.63% | -143.63% | -176.25% | -194.05% |
| InterCure Ltd. (INCR)vs › | $63.02M | 8.84% | -6.43% | -1.20% | -7.11% |
| Spero Therapeutics, Inc. (SPRO)vs › | $68.90M | -0.04% | -76.47% | -54.24% | -650.20% |
| Heron Therapeutics, Inc. (HRTX)vs › | $62.78M | -0.14% | -3.20% | -62.68% | -125.61% |
Gross Margin
0.0%
EBITDA Margin
N/A
Operating Margin
0.0%
Net Margin
0.0%
Formula: EBITDA Margin = (EBITDA / Revenue) × 100
Why EBITDA Margin matters:
EBITDA Margin = EBITDA / Revenue
EBITDA margin measures operating profitability before interest, taxes, depreciation, and amortization as a percentage of revenue.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
